Q32 Bio (QTTB) Cash & Current Investments (2017 - 2026)
Q32 Bio's (QTTB) quarterly Cash & Current Investments came in at $50.8 million in Q1 2026, down 22.5% year-on-year from $65.5 million in Q1 2025, and up 5.08% quarter-over-quarter from $48.3 million in Q4 2025.
Q32 Bio (QTTB) Cash & Current Investments (2017 - 2026) Analysis & Trends
Q32 Bio's Cash & Current Investments history runs 10 years deep, the most recent figure standing at $50.8 million for Q1 2026.
- On a quarterly basis, Cash & Current Investments fell 22.5% year-over-year to $50.8 million in Q1 2026; TTM through Mar 2026 was $50.8 million, a 22.5% decrease from a year earlier, with the FY2025 full-year figure at $48.3 million, up 7364.76% from the prior year.
- Cash & Current Investments climbed to $50.8 million in Q1 2026 per QTTB's latest filing, from $48.3 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $256.1 million in Q1 2022 and bottomed at $647000.0 in Q4 2024.
- The 5-year median for Cash & Current Investments is $79.8 million (2023), against an average of $103.0 million.
- Across the five-year window, Cash & Current Investments slumped 96.77% in 2023 and jumped 7364.76% in 2025, its largest moves.
- Year by year, Cash & Current Investments stood at $175.0 million in 2022, then slumped by 96.77% to $5.6 million in 2023, then tumbled by 88.54% to $647000.0 in 2024, then soared by 7364.76% to $48.3 million in 2025, then increased by 5.08% to $50.8 million in 2026.
- Per Business Quant, the three latest QTTB Cash & Current Investments figures stand at $50.8 million (Q1 2026), $48.3 million (Q4 2025), and $68.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Q32 Bio | 215.94 Mn | 165.19 Mn | - | 50.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.75 Mn |
| Dec 31, 2025 | 48.30 Mn |
| Sep 30, 2025 | 68.94 Mn |
| Jun 30, 2025 | 54.83 Mn |
| Mar 31, 2025 | 65.48 Mn |
| Dec 31, 2024 | 647,000.00 |
| Sep 30, 2024 | 89.08 Mn |
| Jun 30, 2024 | 107.65 Mn |
| Mar 31, 2024 | 135.31 Mn |
| Dec 31, 2023 | 5.65 Mn |
| Sep 30, 2023 | 79.83 Mn |
| Jun 30, 2023 | 70.33 Mn |
| Mar 31, 2023 | 116.22 Mn |
| Dec 31, 2022 | 175.03 Mn |
| Sep 30, 2022 | 201.07 Mn |
| Jun 30, 2022 | 225.52 Mn |
| Mar 31, 2022 | 256.13 Mn |
| Dec 31, 2021 | 157.83 Mn |
| Sep 30, 2021 | 187.55 Mn |
| Jun 30, 2021 | 214.57 Mn |